Skip to content
Gonadorelin
Factrel, Lutrepulse (gonadorelin) is a protein pharmaceutical. Gonadorelin was first approved as Factrel on 1982-09-30. It is used to treat amenorrhea, delayed puberty, ovarian cysts, and precocious puberty in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gonadorelin acetate
Tradename
Company
Number
Date
Products
LUTREPULSE KITFerring PharmaceuticalsN-019687 DISCN1989-10-10
2 products
Hide discontinued
Gonadorelin hydrochloride
Tradename
Company
Number
Date
Products
FACTRELHikma PharmaceuticalsN-018123 DISCN1982-09-30
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
amenorrhea—D000568N91.2
delayed pubertyHP_0000823D011628E30.0
ovarian cystsHP_0000138D010048N83.1
precocious puberty—D011629E22.8
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CA: Gonadotropin-releasing hormones
— H01CA01: Gonadorelin
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CM: Fertility disturbances test diagnostic agents
— V04CM01: Gonadorelin
HCPCS
Code
Description
J1620
Injection, gonadorelin hydrochloride, per 100 mcg
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—1———1
LeukemiaD007938C95—1———1
Myelodysplastic syndromesD009190D46—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGONADORELIN
INNgonadorelin
Description
Gonadorelin is a ten-membered synthetic oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, glycyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence. It has a role as a gonadotropin releasing hormone agonist. It is an oligopeptide and a peptide hormone.
Classification
Protein
Drug classprehormones or hormone-release stimulating peptides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Identifiers
PDB—
CAS-ID33515-09-2
RxCUI6384
ChEMBL IDCHEMBL1007
ChEBI ID5520
PubChem CID638793
DrugBankDB00644
UNII ID9O7312W37G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 559 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
151 adverse events reported
View more details